$24.38 -0.02 (-0.08%)
11/6/2009 4:00 PM

Myriad Genetics, Inc. (MYGN)

CAPS Rating: 4 out of 5

Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.

Current Price $24.38 Mkt Cap $2.35B
Open $24.24 P/E Ratio 16.16
Prev. Close $24.40 Div. (Yield) N/A (N/A)
Daily Range $23.86 - $24.40 Volume 1,694,034
52-Wk Range $23.75 - $47.08 Avg. Daily Vol. 1,404,000

MYGN News and Commentary

Caps

How do you think MYGN will perform vs the S&P 500?

Add Stock to Watchlist

All Members

412 Outperform
28 Underperform
 

All-Star Members

131 Outperform
6 Underperform
 

Wall Street

13 Outperform
2 Underperform
 

Top MYGN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

pshea12 (99.89)
Submitted April 29, 2009

Myriad Genetics has been a name I had been hoping to buy on a pullback since January 2009 - but it refused to fall during the multi week correction in the general market. Now we see why - just a homerun earnings report - the stock ran away from me up… More

e2nelson (62.05)
Submitted April 19, 2007

Myriad Genetics has an Alzheimer drug in 3rd stage clinical testing which will take the better part of a year. In the meantime their other products will produce some growth but it will take a blockbuster like an Alzheimer treatment to get them to the… More

MYGN VS S&P 500 (SPY)

Fools bullish on MYGN are also bullish on:

Fools bearish on MYGN are also bearish on:

Recent Community Commentary

Read the most recent pitches from members about MYGN.

Recs

1
Member Avatar richardrogers4 (65.06) Submitted: 10/29/2009 4:35:19 PM : Outperform Start Price: $24.50 MYGN Score: -1.27

CAPS recommendation for me.

Recs

1
Member Avatar kenc132000 (90.37) Submitted: 10/28/2009 9:52:43 AM : Outperform Start Price: $23.79 MYGN Score: +1.19

New 52 week low. Blowout earnings last quarter. Strong support at $24 last several months.. Good growth prospects.

Recs

1
Member Avatar FitzColinGerald (35.92) Submitted: 10/27/2009 7:20:04 PM : Outperform Start Price: $24.63 MYGN Score: -1.94

Myriad Genetics is a healthcare company that specializes in the development and marketing of prognostic medicine products. Such products include COLARIS and TheraGuide 5-FU, which measure a person's susceptibility to colon cancer and a person's response to 5-FU-based chemotherapy, respectively. These products are becoming increasingly important, as patients wish to assess their potential risks with certain diseases and treatments.

Leaderboard

Find the members with the highest scoring picks in MYGN.

Score Leader

conliskjr

conliskjr (96.30) Score: +221.06

The Score Leader is the member with the highest score across all their picks in MYGN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score Commentary
flighttofreedom 73.13 9/22/2006 9/6/2009 Outperform 3Y $11.76 +107.31% -13.34% +120.65
autocontractor 31.89 9/22/2006 Outperform 1Y $11.77 +107.14% -13.34% +120.48
mattc513 < 20 9/11/2006 Outperform 1Y $11.93 +104.36% -12.05% +116.41
sato1027 35.33 10/4/2006 Outperform 5Y $12.27 +98.70% -14.49% +113.18 1 Comment
dgalbraith100 70.45 8/29/2006 Outperform 3Y $12.25 +99.02% -12.05% +111.07
Moontan38 < 20 9/21/2006 Outperform 5Y $12.40 +96.69% -14.25% +110.95
nlsntomn < 20 8/28/2006 Outperform 1Y $12.31 +98.05% -12.28% +110.33
saeedzee 88.85 8/28/2006 Outperform 3Y $12.34 +97.57% -11.92% +109.49
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. kr0lina 56.78 8/25/2006 7/3/2007 Outperform 3Y $12.38 +97.01% -11.86% +108.87
mayahuel100 75.75 8/25/2006 Outperform 3Y $12.38 +97.01% -11.86% +108.87

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackZacks 69.52 11/6/2009 Underperform 3M $24.38 0% 0% 0 1 Comment
TrackCanaccord 84.17 8/27/2009 Outperform NS $28.74 -15.17% +4.67% -19.84
TrackWMBlair 39.74 8/4/2009 Outperform NS $27.16 -10.24% +7.66% -17.90
TrackSoleil 83.54 7/17/2009 Outperform NS $25.63 -4.88% +14.44% -19.32
TrackMorganJos < 20 7/1/2009 Underperform NS $27.16 -10.24% +16.57% +26.81
TrackPiperJaff 80.38 7/1/2009 Outperform NS $27.16 -10.24% +16.52% -26.76
TrackMorganJos < 20 5/19/2009 Outperform NS $33.44 -18.78% +2.19% -20.97 7/1/2009 @ $27.16
TrackJimCramer < 20 4/1/2009 Outperform 3W $45.07 -45.91% +33.55% -79.45
TrackLeerinkSwan 84.26 3/24/2009 Outperform NS $40.71 -40.11% +33.67% -73.78
TrackZacks 69.52 2/4/2009 Outperform 3M $41.56 -41.33% +30.84% -72.17 11/7/2009 @ $24.38 1 Comment
TrackBenchmark 88.54 2/3/2009 Outperform NS $42.46 -42.58% +31.98% -74.56
TrackCitigroup 21.22 11/21/2008 Outperform NS $31.24 -21.95% +42.52% -64.46
TrackOppenheimer 26.63 10/8/2008 Outperform NS $29.14 -6.79% -2.82% -3.98 7/1/2009 @ $27.16
TrackRBCCapMkts 81.74 7/30/2008 Outperform NS $32.22 -15.72% -27.06% +11.34 7/1/2009 @ $27.16
TrackCanaccord 84.17 6/5/2008 Underperform NS $23.86 +20.45% -26.41% -46.86 8/26/2009 @ $28.74
TrackRBCCapMkts 81.74 5/28/2008 Underperform NS $24.61 -9.40% -8.20% +1.20 6/30/2008 @ $22.30
TrackGarpResearc 86.48 11/28/2007 Outperform NS $23.64 +3.13% -22.16% +25.29
TrackZacks 69.52 8/21/2007 Outperform 3M $21.01 +55.84% -11.97% +67.81 8/20/2008 @ $32.75 1 Comment
TrackUBS 86.41 2/8/2007 Outperform NS $17.83 +36.74% -21.46% +58.20
TrackBroadpoint.AmTech 73.02 2/8/2007 Outperform NS $17.83 +36.74% -21.46% +58.20
TrackJMP < 20 2/7/2007 Outperform NS $17.92 +36.09% -21.65% +57.73
TrackBofASec 93.50 11/2/2006 Outperform NS $13.31 +83.24% -16.64% +99.88

Featured Broker Partners